Survival Comparison of Treatments for Hypertrophic Obstructive Cardiomyopathy

All-cause mortality at 10 years postprocedure was higher with alcohol septal ablation compared with surgical myomectomy.

In this retrospective, observational study, investigators compared long-term survival with two septal reduction therapies — alcohol septal ablation (ASA) and surgical myomectomy — in patients with hypertrophic obstructive cardiomyopathy. Procedures were performed at three high-volume centers over a 20-year period.

Patients undergoing ASA (n=585) were significantly older (median age, 63 vs. 54 years) than those undergoing surgical myomectomy (n=3272) and had more comorbidities, including renal failure, diabetes, hypertension, and coronary artery disease. Procedural and early mortality through 3 years was similar and low in both groups of patients. The estimated unadjusted all-cause mortality rate at 10 years (median follow up, 6.4 years) was …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)